Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.
Biochemical pharmacology
Small-molecule NNMT inhibitor; not a peptide
Also indexed as: NNMT inhibitor
The cited study examines diet-induced obesity in mice, not weight loss in people.
Unfamiliar word? Open this panel for simple explanations, right here.
5 glossary terms used in this profile
Select a word to see its meaning. You can keep more than one definition open.
Definitions explain the words—not whether a molecule works or is safe. Research education only, not medical advice.
5-Amino-1MQ is a synthetic small molecule studied as an inhibitor of the NNMT enzyme. It is included alongside peptides because of its metabolic-research context, but it is not a peptide.
NNMT / cellular metabolism
Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide and methyl-donor metabolism. Experimental work asks how this changes adipose-cell metabolism.
A biological pathway describes a proposed or observed interaction—not necessarily a demonstrated health outcome.
Decode the terminology in our glossaryEarly lab & animal research
Most support comes from cells or animals. These studies help form questions, but do not prove a treatment works in people.
For this research: The cited study examines diet-induced obesity in mice, not weight loss in people.
An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.
Mechanistic laboratory evidence is not separately assessed in this selected-source summary; see references and their study types.
The cited study investigates high-fat-diet-induced obesity in mice.
Associations, biomarker studies and anecdotes cannot establish treatment causality; no observational result is used here to infer clinical effectiveness.
Reliable, independently replicated human outcome evidence is not established by the selected sources in this edition.
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Adipose metabolism and metabolic dysfunction in experimental models.
These describe scientific questions, not prescribing recommendations. A research grouping does not establish combination safety or clinical effectiveness.
Explore research by health goalHuman toxicology, drug interactions and long-term risks are not established. Effects on methylation and NAD metabolism require further study.
This is not an exhaustive safety or contraindication list. An absence of reported harm is not proof of safety. Pregnancy, breastfeeding, cancer history, endocrine disease and concurrent medicines can materially change risk. Unregulated preparations add identity, contamination and sterility risks.
Not FDA-approved
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Regulatory status and evidence strength are different. A nomination for compounding, a clinical-trial registration or a “research use only” label is not approval. International rules vary; consult the current regulator and product label.
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.
Biochemical pharmacology
Matched bibliographic records confirm a publication’s identity, not the validity of every claim. Selected sources are not a systematic literature review.
These open search results, not additional verified citations. Trial registration is not evidence that a treatment works.
Beyond the library
Explore our broader health optimization approach. A library entry does not mean a molecule is offered, prescribed, or appropriate for you.
Continue to our existing activation & intake page.
Education, not a prescription. Research summaries are not medical advice, dosing instructions, or an offer to sell. Mechanistic findings do not establish clinical effectiveness. US regulatory status is product- and indication-specific and may change. Discuss health decisions with a licensed clinician.